Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.
Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.


Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Saturday, April 13, 2013

Encourage Congressional Support for MS Priorities

Over the past two weeks, Members of the House of Representatives have circulated ‘Dear Colleague’ letters, urging members to formally signal support for certain funding priorities. During this time, three letters have been generated in support of funding for MS issues: the National Institutes of Health (NIH), the MS program in the Congressionally Directed Medical Research Program (CDMRP) and the Lifespan Respite Care program. This week, the CDMRP letter was sent to the House Appropriations Committee with 52 co-signers supporting $10 million for fiscal year (FY) 2014. The other two letters will remain open until next week, as additional signatures are collected. Please take a minute to ensure the greatest support for NIH and the Lifespan Respite Care Program by contacting your Member today and urge him/her to co-sign these letters! National MS Society Sponsors Rally for Medical Research On April 8, the Society joined thousands of advocates in Washington, D.C., to call on Congress to increase funding for medical research, which was cut in early March due to sequestration. Nearly 200 organizations and a handful of lawmakers, including MS Caucus co-chair Rep. Chris Van Holler (MD-8), participated in the event, reflecting the importance of research on health and the economy. The sequester, or across the board cuts, reduced the budget for the National Institutes of Health (NIH) by roughly $1.5 billion this year. In addition, the Congressionally Directed Medical Research Programs (CDMRP) within the Department of Defense also faces cuts, with the exact amount to be determined in the upcoming weeks. The Society and others have warned that reductions and uncertainty in research funding will postpone medical breakthroughs and set research back considerably. This message was echoed on Monday, as MS Activists and others sent several thousand emails and text messages to Congress asking them to make research funding a priority. President Releases Budget Plan; Includes Compromises On April 10, President Obama released his proposed budget for fiscal year (FY) 2014. Generally, the President proposes to cancel sequestration and replace it with an additional $1.8 trillion in deficit reduction through new revenue, $400 billion in "health savings," Social Security changes, and $200 billion in discretionary cuts split evenly between defense and nondefense programs. The president’s budget is unlikely to pass Congress or be enacted exactly as proposed, but the document underscores the White House’s priorities. While many programs face potential downsizing, the White House budget proposes a 5 percent increase in funding for the Department of Health and Human Services. The President is requesting $80.1 billion in discretionary funding for the Department of Health and Human Services, up $3.1 billion (5.1 percent) from the $76.2 billion enacted for fiscal 2012. The president's 2014 proposed budget does not reflect recent appropriations or sequestration spending figures (for 2013). Specifically, the Food and Drug administration is slated to receive an increase, with a proposed budget of $4.7 billion, an $821 million increase (or 21 percent) over its 2012 budget. Much of that increase would come from new “user fees” (or charges to the medical device and drug industries the FDA regulates). Additionally, the National Institutes of Health (NIH) budget would increase slightly to $31.2 billion from the $30.7 billion enacted in fiscal year 2012. Conversely, the budget also proposes some reductions in health spending. The budget spells out plans to generate $389 billion through Medicare cuts and other HHS-related savings over a 10-year period. Long-term Care Commission Established As part of the deal that averted the fiscal cliff last December, Congress repealed the Community Living Assistance Services and Supports (CLASS) Program. Planned as a voluntary long-term insurance program, CLASS would have provided a cash benefit to people who become functionally or cognitively impaired and could have helped them maintain their independence and lives in their communities. CLASS was originally enacted as part of health care reform, but was ultimately determined to be financially unsustainable. When it repealed CLASS, Congress established a bipartisan Long-term Care Commission that is tasked with developing policy proposals that could provide more flexible, affordable long-term services and support options. All appointees have now been named to the Commission, which will have six months in which to complete its important work once some administrative details are finalized.

No comments:

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.